Announcements for newly approved specialty drugs often state that the product will be available through specialty pharmacy in limited distribution. However, the press releases rarely specify the specialty pharmacy(ies) selected as the designated partner(s).
Here are three LD deals that have been recently publicly confirmed subsequent to the approvals.
ORSERDU Available through Biologics by McKesson
CARY, N.C., Feb. 10, 2023—Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease areas, was selected by Stemline Therapeutics Inc., as a limited distribution network specialty pharmacy provider for Orserdu (elacestrant).
ORSERDU Available through Onco360
ORSERDU is an estrogen receptor antagonist indicated for the treatment of postmenopausal women or adult men with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, ESR1-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy.
Biologics Named Exclusive Pharmacy for SKYCLARYS (omaveloxolone)
Biologics by McKesson was selected by Reata Pharmaceuticals as the sole specialty pharmacy provider for Skyclarys (omaveloxolone), the first and only treatment for Friedreich’s ataxia (FA). Skyclarys was approved by the U.S. Food and Drug Administration (FDA) on Feb. 28, 2023, for the treatment of FA in adults and adolescents aged 16 years and older, along with a rare pediatric disease priority review voucher.
